Merck (NYSE:MRK) Q4 CY2025 Sales Exceed Expectations, EPS Beat Consensus

[Para 1: The Lead] Merck (NYSE:MRK) surpassed Wall Street revenue forecasts in Q4 CY2025, reporting sales of $16.4 billion, up 5% year-over-year. The company's non-GAAP earnings per share (EPS) of $2.04 surpassed analysts' estimates by 1.5%. Despite missing full-year revenue guidance and EPS projections, Merck's Q4 performance indicates resilience and potential for continued growth. [Para 2-3: Supporting details & Context] Merck's full-year revenue guidance of $66.25 billion was 2% below analyst expectations. However, its non-GAAP profit of $2.04 per share was 1.5% above consensus. The company's strong Q4 performance, driven by its oncology and infectious disease therapies, highlights its competitive edge. Merck's efficiency in revenue generation and profitability, evidenced by a 6.2 percentage point increase in operating margin over the last five years, positions it for sustained growth. Despite the stock's slight dip post-earnings, Merck's Q4 results suggest a strong financial foundation and potential for future earnings.